Learn more about Bexion Pharmaceuticals through our highlights video

Watch the video


Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson

In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.


Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.

Innovation Express magazine cover

Bexion in Innovation Express

Innovation Express is a multi-media healthcare news hub designed to share all Innovation Healthcare Institute (IHCI) events and programs and announce the most innovative items in healthcare. Bexion Pharmaceuticals, Inc. was recently featured in Innovations Express. Please click on the link below to read the article and learn more about our organization.

Read more

– Our Platform

An innovative, targeted approach to treating cancer

For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.

By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials


Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More


Bexion Resources


Learn More
View All Resources


    Press Release

    Bexion Pharmaceuticals, Inc. to Present at the 2022 Association for Cancer Immunotherapy (CIMT) Annual Meeting

    May 10, 2022

    FOR IMMEDIATE RELEASE [Covington, KY---May 10, 2022 ] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for the CIMT annual meeting to be held in Mainz, Germany, May 10-12, 2022 has been chosen for poster presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the ... Read More

      Press Release

      Bexion Pharmaceuticals Announces Leadership Additions

      February 2, 2022

      The new leadership roles support the company’s momentum in becoming the leader in developing and commercializing therapeutics based on exploiting the lysosome to treat challenging solid tumors as well as chemotherapy-induced peripheral neuropathy (CIPN). FOR IMMEDIATE RELEASE [Covington, KY---February 2, 2022] Bexion Pharmaceuticals, a clinical stage biopharmaceutical company, today announced key leadership changes, including the ... Read More

      View All Media